EUVIMEDEUVIMED entdecken
Crossref

Efficacy of new antimicrobial agents against carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacterales in Japan: national genomic surveillance (JARBS 2.0) study

Norikazu Kitamura iD, Hirokazu Yano iD, Sayoko Kawakami iD, Sadao Aoki iD, Eiko Anzai, Satoyo Wakai, Maki Okuda, Yoshie Taki, Aki Hirabayashi iD, Yumiko Hosaka iD, Toshiki Kajihara iD, Yo Sugawara iD und 2 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Norikazu Kitamura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan. Hauptthemen laut MEDLINE: beta-Lactamases, Bacterial Proteins, Carbapenem-Resistant Enterobacteriaceae, Anti-Bacterial Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Integrated genomic and phenotypic surveillance is essential to address the global spread of antimicrobial resistance. Conventional surveillance systems monitor resistance to established agents but often lack susceptibility data for newly developed antimicrobials, limiting evidence-based treatment selection.

Objectives

To characterize the genomic epidemiology and antimicrobial susceptibility of Enterobacterales with reduced meropenem susceptibility in Japan using the upgraded Japan Antimicrobial Resistant Bacterial Surveillance system (JARBS 2.0).

Methods

In 2023, 873 Enterobacterales isolates with reduced meropenem susceptibility were collected from 82 hospitals and subjected to whole-genome sequencing. Standardized quantitative susceptibility testing, including seven recently developed antimicrobial agents (particularly nacubactam-based combinations under regulatory review), was performed for carbapenemase-producing Enterobacterales (CPE) and non-carbapenemase-producing carbapenem-resistant Enterobacterales (non-CP CRE).

Results

Carbapenemase genes were detected in 101 isolates (11.6%), predominantly blaIMP (85%) and blaNDM (9%), demonstrating the predominance of metallo-β-lactamases (MBLs) in Japan. Among MBL producers, susceptibility rates were ≥96% for cefiderocol, cefepime/nacubactam, aztreonam/nacubactam, and aztreonam/avibactam. Among non-CP CRE isolates, only cefepime/nacubactam maintained similarly high activity. Notably, 13% of carbapenemase-producing isolates remained phenotypically susceptible to meropenem (MIC ≤1 mg/L), representing “stealth” MBL carriers.

Conclusions

Nacubactam-based combinations, cefiderocol and aztreonam/avibactam show promise against MBL-producing Enterobacterales in Japan, whereas cefepime/nacubactam demonstrated the greatest activity against non-CP CRE. The upgraded JARBS 2.0 framework enables high-resolution genomic and phenotypic surveillance, bridging the gap between molecular resistance mechanisms and the clinical efficacy of emerging antimicrobial agents. These findings highlight the value of integrating genomic surveillance into routine monitoring to guide antimicrobial therapy and inform infection prevention and control strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesBacterial ProteinsCarbapenem-Resistant EnterobacteriaceaeAnti-Bacterial AgentsEnterobacteriaceae InfectionsEnterobacteriaceaeJapanHumansMicrobial Sensitivity TestsWhole Genome SequencingCefiderocolMeropenemCarbapenemsThird Generation Cephalosporins

Substanzen

beta-LactamasesBacterial ProteinsAnti-Bacterial AgentscarbapenemaseCefiderocolMeropenemCarbapenemsThird Generation Cephalosporins

Autor:innen und Institutionen

  • Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.

ORCID-Profile: Norikazu Kitamura, Hirokazu Yano, Sayoko Kawakami, Sadao Aoki, Aki Hirabayashi, Yumiko Hosaka, Toshiki Kajihara, Yo Sugawara, Motoyuki Sugai, Koji Yahara

Förderung

  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Kitamura, N., Yano, H., Kawakami, S., Aoki, S., Anzai, E., Wakai, S., Okuda, M., Taki, Y., Hirabayashi, A., Hosaka, Y., Kajihara, T., Sugawara, Y., Sugai, M., & Yahara, K. (2026). Efficacy of new antimicrobial agents against carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacterales in Japan: national genomic surveillance (JARBS 2.0) study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag305

Vancouver

Kitamura N, Yano H, Kawakami S, Aoki S, Anzai E, Wakai S, et al. Efficacy of new antimicrobial agents against carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacterales in Japan: national genomic surveillance (JARBS 2.0) study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag305

BibTeX
@article{Kitamura2026,
  author = {Kitamura, Norikazu and Yano, Hirokazu and Kawakami, Sayoko and Aoki, Sadao and Anzai, Eiko and Wakai, Satoyo and Okuda, Maki and Taki, Yoshie and Hirabayashi, Aki and Hosaka, Yumiko and Kajihara, Toshiki and Sugawara, Yo and Sugai, Motoyuki and Yahara, Koji},
  title = {Efficacy of new antimicrobial agents against carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacterales in Japan: national genomic surveillance (JARBS 2.0) study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag305}
}
Kostenlos starten →